Back to top
more

Vertex Pharmaceuticals Incorporated (VRTX)

(Real Time Quote from BATS)

$213.10 USD

213.10
729,782

-0.77 (-0.36%)

Updated May 6, 2021 03:55 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (222 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.

Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 7.58% and 3.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News

The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y

CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.

What's in Store for Vertex (VRTX) This Earnings Season?

On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates

The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.

Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership

Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $220.16, marking a +0.45% move from the previous day.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $217.13 in the latest trading session, marking a +0.55% move from the prior day.

Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More

The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.

Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $211.54, moving -0.96% from the previous trading session.

The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China

The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China

Sheraz Mian headshot

Top Analyst Reports for Abbott, AstraZeneca & Booking Holdings

Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), AstraZeneca (AZN), and Booking Holdings (BKNG).

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $215.15 in the latest trading session, marking a +0.4% move from the prior day.

bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study

bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.

Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

Kaustav Ghosh headshot

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More

Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.

Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.